Literature DB >> 1800127

Gliclazide: a general free radical scavenger.

N A Scott1, P E Jennings, J Brown, J J Belch.   

Abstract

Free radical mechanisms have been implicated in diabetic microangiopathy. Agents that scavenge free radicals may be beneficial. We assessed the scavenging ability of two sulphonylureas, gliclazide and glibenclamide, in vitro. The assay which employs o-dianisidine sensitised by riboflavin can be used to distinguish between superoxide scavengers and general scavengers. The former species lead to an augmentation while the latter has an inhibitory effect. The drugs were added in final concentrations of 0.5, 1.0, 2.5 and 5.0 micrograms/ml. The percentage inhibition (mean +/- S.D.) for each concentration of gliclazide respectively was 11.0 +/- 2.5%, 20.8 +/- 2.9%, 31.4 +/- 2.2% and 47.2 +/- 0.8%. Glibenclamide had no scavenging effects. The results demonstrate that gliclazide is a powerful general free radical scavenger in vitro. We postulate that this scavenging quality of gliclazide may be important in diabetes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1800127     DOI: 10.1016/0922-4106(91)90069-t

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics.

Authors:  Momir Mikov; Maja Đanić; Nebojša Pavlović; Bojan Stanimirov; Svetlana Goločorbin-Kon; Karmen Stankov; Hani Al-Salami
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-06       Impact factor: 2.441

2.  Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes.

Authors:  N Katakami; Y Yamasaki; R Hayaishi-Okano; K Ohtoshi; H Kaneto; M Matsuhisa; K Kosugi; M Hori
Journal:  Diabetologia       Date:  2004-11-24       Impact factor: 10.122

Review 3.  Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus.

Authors:  K J Palmer; R N Brogden
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

Review 4.  Gliclazide modified release.

Authors:  Jane K McGavin; Caroline M Perry; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Suppression of KATP channel activity protects murine pancreatic beta cells against oxidative stress.

Authors:  Belinda Gier; Peter Krippeit-Drews; Tatiana Sheiko; Lydia Aguilar-Bryan; Joseph Bryan; Martina Düfer; Gisela Drews
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

6.  Gliclazide does not fully prevent 2-deoxy-D-ribose-induced oxidative damage because it does not restore glutathione content in a pancreatic β-cell line.

Authors:  Gwanpyo Koh; Min-Kyoung Kim; Eun-Jin Yang; Dae-Ho Lee
Journal:  Oxid Med Cell Longev       Date:  2012-01-19       Impact factor: 6.543

7.  Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells.

Authors:  Agnieszka Sliwinska; Aneta Rogalska; Marzena Szwed; Jacek Kasznicki; Zofia Jozwiak; Jozef Drzewoski
Journal:  Mol Biol Rep       Date:  2011-12-20       Impact factor: 2.316

8.  The in vitro free radical scavenging activity of tenidap, a new dual cyclo-oxygenase and 5-1ipoxygenase inhibitor.

Authors:  C S Lau; J J Belch
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.